Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00017628 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis

A Phase 1 study of Multiple Sclerosis, sponsored by Northwestern Memorial Hospital.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
2
Study locations

NCT00017628: Completed Phase 1 study of Multiple Sclerosis, sponsored by Northwestern Memorial Hospital.

NCT00017628 is a Phase 1 study of Multiple Sclerosis that has completed, run by Northwestern Memorial Hospital. The registered enrollment target is 20 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00017628, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Northwestern Memorial Hospital.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

OBJECTIVES: I. Determine the efficacy, in terms of disease progression, of high-dose cyclophosphamide and total body irradiation with T lymphocyte-depleted autologous peripheral blood stem cell or bone marrow rescue in patients with multiple sclerosis.

Conditions Studied

Interventions

  • DRUG cyclophosphamide
  • DRUG methylprednisolone
  • DRUG filgrastim
  • PROCEDURE Autologous Stem Cell Transplantation

Study Locations (2)

Illinois

  • Northwestern Memorial Hospital - Chicago
  • Rush-Presbyterian-St. Luke's Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2001-04
Phase Phase 1
Northwestern Memorial Hospital

1 total trials

What the finished NCT00017628 record still lists

NCT00017628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 4 interventions - of which cyclophosphamide is the first listed.

NCT00017628 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00017628 about?

NCT00017628 is a clinical study titled "Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis". OBJECTIVES: I. Determine the efficacy, in terms of disease progression, of high-dose cyclophosphamide and total body irradiation with T lymphocyte-depleted autologous peripheral blood stem cell or bone marrow rescue in patients with multiple sclerosis.

What is the current status of trial NCT00017628?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2001-04.

What conditions does trial NCT00017628 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT00017628?

The interventions under investigation include: cyclophosphamide (DRUG), methylprednisolone (DRUG), filgrastim (DRUG), Autologous Stem Cell Transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00017628?

This trial is sponsored by Northwestern Memorial Hospital, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00017628 being conducted?

This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00017628's enrollment target sits among peer trials

20 262nd of 315 higher than 41 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00017628, the US trial registry maintained by the National Library of Medicine. NCT00017628 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.